Wissenschaftl. Titel | A study to evaluate adverse events and change in disease activity of subcutaneous (SC) epcoritamab in combination with oral and intravenous anti-neoplastic agents in adult participants with Non-Hodgkin Lymphoma Phase 1b/2, open-label study to evaluate safety and tolerability of Epcoritamab in combination with anti-neoplastic agents in subjects with Non-Hodgkin Lymphoma Non-Hodgkin Lymphoma: Epcoritamab in Combination with Anti-Neoplastic Agents |
Erkrankung |
Haema:
NHL:
Erstlinie
|
Kurzprotokoll | Kurzprotokoll |
Links | Weiterführende Informationen (U) Weiterführende Informationen (EudraCT) |
erstellt 21.12.2023 Data entry III CCP
geändert 27.06.2024 Data entry IX CCP